| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, California.
Correspondence: Address correspondence and reprint requests to: Roderich E. Schwarz, MD, PhD, Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ 08903-2681; Fax: 732-235-8098; E-mail: r.schwarz{at}umdnj.edu
Background: A recent Intergroup trial demonstrated a significant survival advantage of postgastrectomy chemoradiation in gastric cancer patients, primarily because of a reduction of a relative locoregional recurrence (LRR) rate exceeding 70% in control patients. Radical gastrectomy with extended lymphadenectomy may reduce LRR, possibly affecting adjuvant treatment strategies.
Methods: Information on patients undergoing gastrectomy for potentially curable gastric cancer between 1990 and 2000 was reviewed. Patterns of first disease recurrence, survival, and disease-free survival were calculated, and predictors were identified.
Results: Gastrectomies were performed in 73 patients, with R0 resections in 82%. The median lymph node count was 24; positive nodes were found in 64% of patients. The median actuarial survival was 27 months, with a 5-year survival of 37%. Disease recurred in 35 patients (48%) after a median interval of 7 months (range, .5–67). Recurrent disease patterns included distant only (37%), peritoneal only (23%), peritoneal/locoregional (17%), all sites combined (14%), locoregional only (6%), and distant/locoregional (3%). Recurrence predictors were N3 category for distant recurrence (hazard ratio [HR], 10.2; P = .005), T3/4 category for peritoneal recurrence (HR, 4.8; P = .008), peritoneal relapse (HR, 40; P = .002), and a prior abdominal operation for LRR (HR, 3.2; P = .01). N2 disease had a distant failure risk similar to N1 status and an intraperitoneal failure risk similar to an N3 category.
Conclusions: Isolated LRR of gastric cancer after gastrectomy and extended lymphadenectomy is rare in this series. Most recurrences appeared diffusely at distant or peritoneal sites, and most LRRs occurred in conjunction with relapse at extraregional sites. Pathologic predictors of intraperitoneal (T3/4) or systemic failure (>N1) could be used to guide individualized, risk-oriented, adjuvant treatment.
Key Words: Gastric cancer • Locoregional recurrence • Extended lymph node dissection • Recurrence rate
This article has been cited by other articles:
 |
|
 |
|
  R. E. Schwarz and D. D. Smith Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage Ann. Surg. Oncol., February 1, 2007; 14(2): 317 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Smith, R. R. Schwarz, and R. E. Schwarz Impact of Total Lymph Node Count on Staging and Survival After Gastrectomy for Gastric Cancer: Data From a Large US-Population Database J. Clin. Oncol., October 1, 2005; 23(28): 7114 - 7124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Schwarz and D. D. Smith Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial J. Clin. Oncol., August 10, 2005; 23(23): 5404 - 5405. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Elaraj and S. E. Ettinghausen Cytological Analysis of Peritoneal Washings: Now Part of the Standard Preoperative Staging Evaluation for Patients With Resectable Gastric Cancer? Ann. Surg. Oncol., May 1, 2005; 12(5): 339 - 341. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sako, J. Kitayama, H. Koyama, H. Ueno, H. Uchida, H. Hamada, and H. Nagawa Transduction of Soluble Flt-1 Gene to Peritoneal Mesothelial Cells Can Effectively Suppress Peritoneal Metastasis of Gastric Cancer Cancer Res., May 15, 2004; 64(10): 3624 - 3628. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
